Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MSH2 knock-down shows CTG repeat stability and concomitant upstream demethylation at the DMPK locus in myotonic dystrophy type 1 human embryonic stem cells.
Franck S, Barbé L, Ardui S, De Vlaeminck Y, Allemeersch J, Dziedzicka D, Spits C, Vanroye F, Hilven P, Duqué G, Vermeesch JR, Gheldof A, Sermon K. Franck S, et al. Among authors: de vlaeminck y. Hum Mol Genet. 2021 Jan 6;29(21):3566-3577. doi: 10.1093/hmg/ddaa250. Hum Mol Genet. 2021. PMID: 33242073
Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model.
Ertveldt T, De Beck L, De Ridder K, Locy H, de Mey W, Goyvaerts C, Lecocq Q, Ceuppens H, De Vlaeminck Y, Awad RM, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K, Krasniqi A. Ertveldt T, et al. Among authors: de vlaeminck y. Mol Cancer Ther. 2022 Jul 5;21(7):1136-1148. doi: 10.1158/1535-7163.MCT-21-0791. Mol Cancer Ther. 2022. PMID: 35499391 Free PMC article.
Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma.
De Beck L, Awad RM, Basso V, Casares N, De Ridder K, De Vlaeminck Y, Gnata A, Goyvaerts C, Lecocq Q, San José-Enériz E, Verhulst S, Maes K, Vanderkerken K, Agirre X, Prosper F, Lasarte JJ, Mondino A, Breckpot K. De Beck L, et al. Among authors: de vlaeminck y. Front Immunol. 2022 May 12;13:799636. doi: 10.3389/fimmu.2022.799636. eCollection 2022. Front Immunol. 2022. PMID: 35634329 Free PMC article.
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Awad RM, Lecocq Q, Zeven K, Ertveldt T, De Beck L, Ceuppens H, Broos K, De Vlaeminck Y, Goyvaerts C, Verdonck M, Raes G, Van Parys A, Cauwels A, Keyaerts M, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: de beck l, de vlaeminck y. Mol Ther Methods Clin Dev. 2021 Jun 4;22:172-182. doi: 10.1016/j.omtm.2021.05.017. eCollection 2021 Sep 10. Mol Ther Methods Clin Dev. 2021. PMID: 34485603 Free PMC article.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: de vlaeminck y. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Cancer-Associated Myeloid Regulatory Cells.
De Vlaeminck Y, González-Rascón A, Goyvaerts C, Breckpot K. De Vlaeminck Y, et al. Front Immunol. 2016 Mar 29;7:113. doi: 10.3389/fimmu.2016.00113. eCollection 2016. Front Immunol. 2016. PMID: 27065074 Free PMC article. Review.
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. De Vlaeminck Y, et al. J Control Release. 2019 Apr 10;299:107-120. doi: 10.1016/j.jconrel.2019.02.023. Epub 2019 Feb 21. J Control Release. 2019. PMID: 30797866
23 results